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Scott R. Solomon,1 Connie A. Sizemore,1 Melissa Sanacore,1 Xu Zhang,2 Stacey Brown,1
H. Kent Holland,1 Lawrence E. Morris,1 Asad Bashey1Haploidentical hematopoietic stem cell transplant (HSCT) provides an opportunity for nearly all patients to
benefit from HSCT. We conducted a trial of haploidentical T cell replete allografting using a busulfan-based
myeloablative preparative regimen, peripheral blood stem cells (PBSCs) as the graft source, and posttrans-
plantation cyclophosphamide (Cy). Eligibility was limited to patients at high risk of relapse after nonmyeloa-
blative haploidentical bone marrow transplant (BMT). Twenty patients were enrolled in the study (11 with
relapsed/refractory disease and 9 who underwent transplantation while in remission and considered stan-
dard risk). Donor engraftment occurred in all 20 patients with full donor T cell and myeloid chimerism by
day 130. The cumulative incidence of grades II-IV and III-IV acute graft-versus-host disease (aGVHD) was
30% and 10%, respectively. The cumulative incidence of chronic GVHD (cGVHD) was 35%. Nonrelapse mor-
tality (NRM) at 100 days and 1 year was 10% for all patients and 0% for standard-risk patients. With a median
follow-up of 20 months, the estimated 1-year overall survival (OS) and disease-free survival (DFS) was 69%
and 50%, respectively, for all patients, and 88% and 67% for standard-risk patients. Myeloablative
haploidentical HSCT is associated with excellent rates of engraftment, GVHD, NRM, and DFS, and is a valid
option in patients with high-risk malignancies who lack timely access to a conventional donor.
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Interest in haploidentical hematopoietic stem cell
transplant (HSCT) originates from the immediate
and almost universal availability of a one haplotype-
mismatched family donor. This is a critical issue for
the 70% of patients who do not have an available
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unrelated donor (VUD) can identify a compatible
donor for an additional 30% to 40% of patients. The
chance of finding a suitable donor in the VUD registry
significantly depends upon the racial and ethnic back-
ground of the transplantation recipient, ranging from
60% to 70% in whites, to about 10% to 20% for ethnic
minorities. Furthermore, the successful application of
VUD transplantation is hindered by the amount of
time it takes from search initiation to allograft pro-
curement. Many patients relapse or become ill while
waiting for a VUD transplantation to begin. In con-
trast, a haploidentical family member can be identified
and mobilized immediately in nearly all cases.
Until recently, haploidentical HSCT has been
associated with disappointing clinical outcomes,
limiting the widespread acceptance of this approach.
Historically, T cell replete HSCT from haploidentical
donors, using conventional posttransplantation immu-
nosuppression, resulted in unacceptably high rates of1859
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and nonrelapse mortality (NRM) [1,2]. To address
the risk of engraftment failure and GVHD, the
Perugia Group pioneered a transplantation strategy
based on antithymocyte globulin (ATG)-containing
intensive conditioning, high peripheral blood stem
cell (PBSC) content (median: 107 CD341 cells/kg),
and extensive ex vivo T cell depletion (median: 2 
104 CD31 cells/kg), which resulted in very low rates
of graft rejection and GVHD [3]. However, as a result
of the low T cell dose, the risk of serious infection and
death from prolonged immune compromise in these
patients remains high, with NRM estimated to be ap-
proximately 40%. Despite this, event-free survival
rates for patients with high-risk acute leukemia is
very promising, with 40% to 50% of patients who
undergo transplantation while in remission surviving
leukemia-free [4].
Investigators from Johns Hopkins University have
pioneered an alternative approach to haploidentical
HSCT strategy using a nonmyeloablative preparative
regimen, followed by a T cell replete (unmanipulated)
bone marrow (BM) graft. Posttransplantation high-
dose cyclophosphamide (Cy) was administered on
day 13 and 14 to control both GVHD and graft re-
jection in combination with tacrolimus and mycophe-
nolate mofetil (MMF) [5]. This approach results in
very low NRM (4% and 15% at 1 and 2 years, respec-
tively) due to low rates of GVHD and infectious
complications. Immune reconstitution was promising
with low risk of cytomegalovirus (CMV) or invasive
mold infections. Event-free survival at 1 and 2 years
was 34% and 26%, respectively, with lymphoidmalig-
nancies responding significantly better than myeloid
malignancies. Relapse was the major cause of treat-
ment failure in this high-risk population of patients
with poor-risk malignancies. Myeloablative condi-
tioning and mobilized PBSC grafts have not been
extensively studied in conjunction with T replete
haploidentical transplantations using posttransplan-
tation Cy.
In order to address the problem of relapse after
nonmyeloablative T replete bone marrow transplant
(BMT), we developed a phase II pilot study usingmye-
loablative conditioning with a PBSC graft for T cell
replete haploidentical transplantation. Intensification
of the preparative regimen has been associated with
a decreased risk of relapse after transplantation in
high-riskmalignancies, particularlymyeloidmalignan-
cies [6]. In addition, the use of PBSC, rather than a BM
graft, is associated with a higher incidence of chronic
graft-versus-host disease (cGVHD) but decreased re-
lapse rates, resulting in improvements in overall sur-
vival (OS) and disease-free survival (DFS) in patients
with advanced stage hematologic malignancies [7].
Our study targeted younger patients, without
a readily available matched related or unrelated donor(URD), who were perceived to be at a prohibitively
high risk of relapse after a nonmyeloablative haploi-
dentical BMT. The primary goal was to assess whether
this approach would allow reliable engraftment with
early donor T cell chimerism, and low rates of
GVHD, infectious complications, and NRM. We
also wanted to estimate the rate of relapse, event-free
survival, and OS.PATIENTS AND METHODS
Patients and Donors
Twenty patients were accrued to this protocol.
Written informed consent was obtained for all of the
patients in accordance with the Declaration of Hel-
sinki. The study was approved by the Institutional
Review Board at Northside Hospital. Patients were
eligible for inclusion if they were between 18 and 60
years of age, had a high-risk hematologic malignancy,
were without a readily available matched related or
URD, and had adequate organ function as defined by
bilirubin\2, creatinine\2, cardiac ejection fraction
$45%, pulmonary function$50% predicted, Karnof-
sky performance status $70%, and were human
immunodeficiency virus negative. Donors were first-
degree relatives (parent, child, or sibling) of the recip-
ient and were matched at 3/6 to 5/6 loci (HLA-A,
HLA-B, or HLA-DR) with the recipient. Donors
were preferentially selected to minimize HLA mis-
match in the host-versus-graft (HVG) direction. In
addition, donors were selected to avoid a positive
HLA crossmatch in the HVG direction or high-titer,
donor-specific Abs as determined by the pretransplan-
tation panel reactive Ab testing.
Conditioning Regimen and Postgrafting
Immunosuppression
Initial transplantation conditioning consisted
of fludarabine 30 mg/m2/d on days 27 to 22, i.v. bu-
sulfan 130 mg/m2/d on days 27 to 24, and Cy 14.5
mg/kg/d on days 23 and 22 in the first 5 patients.
In response to increased rates of mucositis, fludarabine
and busulfan doses were decreased by 30% and 15%,
respectively, in the 15 subsequent patients (fludarabine
25 mg/m2/d on days 26 to 22, i.v. busulfan 110
mg/m2/d on days 27 to 24, and Cy 14.5 mg/kg/d on
days23 and22). On day 0, patients received an unma-
nipulated PBSC allograft with a CD34 dose capped at
5  106/kg recipient weight. On days 13 and 14,
patients received 2 doses of Cy 50 mg/kg/d with
Mesna. Posttransplantation immunosuppression was
initiated on day 15 with i.v. tacrolimus (target level
5-15 ng/mL) and oral MMF (15 mg/kg 3 times daily
with a maximum daily dose of 3 gm). No immuno-
suppressive agents were administered until 24 hours
after the last dose of posttransplantation Cy, including
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ued without taper at days135 and1180, respectively,
in the absence of GVHD.
Supportive Care
Antimicrobial prophylaxis was administered ac-
cording to institutional practice guidelines. Standard
prophylaxis was started on day 0 including a quinolone
antibiotic and acyclovir. Antifungal prophylaxis con-
sisted of an echinocandin (caspofungin or micafungin)
until day15, when the patient was started on oral ther-
apy with either voriconazole or posaconazole. Filgras-
tim 5 mg/kg was given daily starting on day 15 and
continuing until neutrophil engraftment. Standard
pneumocystis prophylaxis was started on day 130
and continued at least 6 months posttransplantation
and until immunosuppression was discontinued.
Quantitative CMV PCR was monitored weekly start-
ing on day11 and pre-emptive therapy initiated if viral
reactivation was detected ($400 copies/mL).
Chimerism Analysis
We assessed donor–recipient chimerism by the
PCR-based amplification of a polymorphic short tan-
dem repeat regions, followed by fragment separation
by high resolution capillary electrophoresis (ABI
3130 XLGenetic Analyzer, Life Technologies, Grand
Island,NY) and quantitation usingGeneMapper Soft-
ware (Life Technologies). Peripheral blood samples
were collected for chimerism analysis on days 30, 60,
and 90 after transplantation. Samples were separated
into myeloid and T cell lymphoid fractions by indirect
sorting with immunomagnetic beads (StemCell Tech-
nologies, Vancouver, British Columbia, Canada). Pri-
mary Abs were specific to CD33 and CD66b for
myeloid cell and to CD3 for lymphoid T cell fraction-
ation, respectively. The quality of sort was assessed
using multiparametric flow cytometry (FACSCanto
cytometer, DIVA analysis software; BD BioSciences,
San Jose, CA). Genomic DNA was extracted from
immunosorted cells and multiplex PCR was per-
formed using commercial fluorescently labeled primer
sets (ProfilerPlus, COfiler, NGM kits; Life Technol-
ogies). Four or 5-color fluorescence detection was
performed on ABI 3130xl Genetic Analyzer and quan-
tified using GeneMapper Software. For each informa-
tive short tandem repeat loci, allelic peak heights were
determined, and the percentage of host alleles were
calculated as [S(host alleles peak height)/(S(host 1
donor alleles peak heights)]*100. The range of the
error of chimerism was determined to be nonuniform
between different levels of chimerism and did not
exceed 3.23%; 6.66%; 8.33%; 8.89%; 8.60%;
5.31%; and 3.07% for 1% to 5%; 6% to 20%; 21%
to 40%; 41% to 60%; 61% to 80%; 81% to 95%;
and 95% to 99% host, respectively. Ranges for chime-rism error assessment were selected empirically in our
laboratory.
Definitions and Study Endpoints
Neutrophil engraftment was defined as the first of
3 days of an absolute neutrophil count of.0.5 109/L
after transplantation. Platelet engraftment was defined
as a platelet count of .20,000/mL without transfusion
for the 7 preceding days. Acute GVHD (aGVHD) was
scored based on the modified Keystone criteria [8].
Grades III-IV a GVHD were termed ‘‘severe’’ a
GVHD. Chronic GVHD diagnosis and grading were
based on the National Institutes of Health consensus
criteria [9]. Patient outcomes are reported as of De-
cember 31, 2011. Themajor study endpoints were sus-
tained donor engraftment, incidence and severity of
GVHD, and NRM. Patients were considered to have
died of NRM if there was no evidence of disease
relapse or progression before death.
Statistical Methods
Probabilities of OS and DFS were estimated using
the Kaplan-Meier product-limit method [10]. The
cumulative incidents rates of NRM, relapse, aGVHD,
and cGVHD were computed to take account of the
presence of competing risks [11]. All survival outcomes
were assessed between the relapsed/refractory group
and the standard risk group at day 100 and 1 year,
respectively, using the Wald test [11]. A survival
outcome was determined to be significantly diffe-
rent between these 2 groups if the observed P value
was\.05.RESULTS
Patient and Graft Characteristics
A total of 20 patients with a median age of 44 years
(range: 25-56 years) with high-risk hematologic malig-
nancies were treated between January 2009 and March
2011. Patient characteristics are listed in Table 1.
Eleven patients underwent transplantations with re-
lapsed/refractory disease (acute myelogenous leuke-
mia [AML]-5, chronic myelogenous leukemia-blast
crisis [CML-BC]-1, acute lymphoblastic leukemia-2,
non-Hodgkin lymphoma-1, Hodgkin’s disease-1,
chronic lymphocytic leukemia/Richters-1). Nine
patients underwent transplantation with standard-
risk disease (AML CR1 with poor-risk cytogenetics
and/or induction failure, chronic myelogenous
leukemia-chronic phase resistant to all tyrosine kinase
inhibitors). Characteristics of the donors and allografts
are listed in Table 2. The median (range) of HLA
mismatch between donor and recipient was 5 (range:
2-5). Eighty percent of donor–recipient pairs were
mismatched for at least 4 HLA loci.
Table 1. Patient Characteristics
Patients
(n 5 20) Disease
Gender
Male 9 Relapsed/refractory 11
Female 11 AML 5
ALL 2
Age (years) NHL (CLL-Richter [1 patient]) 2
Median (range) 44 (25-56) HD 1
CML-BC 1
Preparative regimen
Flu/Bu/Cy 20 Standard risk 9
AML CR1 high risk 6
Stem cell source Karyotype
Peripheral blood 20 AML CR1 FLT3+ 1
CML-TKI resistant 2
HLA match
5/10 14 HCT-CI
6/10 2 0 9
7/10 3 1-2 9
8/10 1 3-5 2
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leu-
kemia; HD, Hodgkin’s disease; CML-BC, chronic myelogenous leukemia-
blast crisis; Flu, fludarabine; BU, busulfan; Cy, cyclophosphamide; TKI,
tyrosine kinase inhibitor; HCT-CI, hematopoietic cell transplant comor-
bidity index.
Figure 1. Posttransplantation fever curves. Points represent the Tmax
of individual patients for the preceding 24 hours.
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Donor engraftment occurred in all 20 patients,
with a median time to neutrophil and platelet recovery
of 16 days (range: 14-21 days) and 27 days (range:
16-56 days), respectively. There were no late graft fail-
ures. Achievement of full donor chimerism was rapid
with all evaluable patients achieving durable complete
donor T cell and myeloid chimerism by day 130.Regimen-Related Toxicity and Infectious
Complications
Noninfectious fever (median Tmax 103.9; 101.2-
106.8) developed in 18 of 20 patients within a median
of 2.5 days (range: 1-5 days) transplantation and
resolved in all patients after posttransplantation Cy
administration (Figure 1). Excluding CMV reactiva-
tion, a total of 9 grade$III infections (severe, systemicTable 2. Donor and Allograft Characteristics
Donors/Allografts (n 5 20)
Median donor age (range) 44 (20-70)
Donor–recipient relationship
Parent–child 3
Sibling–sibling 13
Child–parent 4
Donor–recipient gender matching
Male/Male 6
Male/Female 3
Female/Male 5
Female/Female 6
Allograft characteristics
Median CD34 dose (range) (x10e6/kg) 5.02 (4.03-5.08)
Median CD3 dose (range) (x10e7/kg) 17.35 (5.85-33.25)infection requiring i.v. antibiotic or antifungal treat-
ment, or hospitalization) occurred in 8 of 20 patients
(40%) before day 30 (bacteremia: 5 patients; bacterial
pneumonia: 1 patient; and viral pneumonia: 2 patients;
Table 3). Two patients developed early fatal respira-
tory infections (Burkholderia Cepacia: 1 patient; and
parainfluenza type 3: 1 patient). No invasive mold
infections were detected. CMV reactivation ($400
copies/mL) occurred in 13 of 16 at-risk patients
(81%) and was treated pre-emptively, per institutional
guidelines. CMV disease developed in only 1 patient
(non-fatal enteritis on day 135 resolved promptly
with treatment). One unexpected finding was a high
rate of BK virus-associated cystitis, affecting 75% of
patients and severe (requiring hospital admission for
bladder irrigation and/or pain management) in 35%.
The median posttransplantation day for developing
cystitis was day 38 (range: 10-75 days).GVHD and NRM
The cumulative incidence of grades II-IV and
grades III-IV aGVHDwas 30% and 10%, respectively
(Figure 2). Grades II-IV aGVHD was seen at a lower
frequency in standard-risk patients compared with
patients with relapsed/refractory disease (11% versus
46%; P 5 .045). With a median follow-up ofTable 3. Grade$3 Infections to Day +30 Posttransplantation
Patients (n 5 20)
No. of patients with grade $3 infections 8
No. of grade $3 infections 9
Bacteremia 5
MRSE 3
Stenotrophomonas 2
Pneumonia 3
RSV 1
Parainfluenza, type 3 1
Burkholderia cepacia 1
MRSE indicates methicillin-resistant Staphylococcus epidermidis; RSV,
respiratory syncytial virus.
Figure 2. Cumulative incidence of (A) acute graft-versus-host disease
(GVHD) and (B) chronic GVHD.
Figure 3. Probability of (A) overall and disease-free survival and (B)
relapse and nonrelapse mortality.
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tients, the cumulative incidence of cGVHD was 35%
and was severe in 5% of patients (Figure 2). There
were no deaths attributable to aGVHD. One patient
died approximately 20 months posttransplantation of
bronchiolitis obliterans syndrome in the setting of
cGVHD. NRM was 10% at 100 days and 1 year. For
standard-risk patients, NRM was 0% at 100 days and
1 year.
Relapse, DFS, and OS
One-year estimates of OS, DFS, and relapse were
69%, 50%, and 40%, respectively, (Figure 3) for all
patients, and 88%, 67%, and 33%, respectively, for
standard-risk patients. After a median follow-up of
20 months, 9 patients remain alive and 8 of these re-
main disease-free. Causes of death are listed inTable 4.Table 4. Causes of Death
Patients (n 5 20)
Relapse/progression 7
NRM 4
Respiratory failure 2
Parainfluenza pneumonia [1 patient]
Bacterial pneumonia [1 patient]
Septic shock 1
cGVHD/BOS 1
NRM indicates nonrelapse mortality; cGVHD, chronic graft-versus-host
disease; BOS, bronchiolitis obliterans syndrome.DISCUSSION
In this report, we describe 20 adult patients with
advanced hematologic malignancies who received
myeloablative, T cell replete haploidentical PBSC
transplants. Despite the presence of a median of 5 mis-
matches in the HVG direction, durable donor engraft-
ment of T cells and hematopoietic cells was seen in all
patients. The cumulative incidence rates of aGVHDand cGVHD were 30% and 35%, respectively, which
are similar, if not slightly less, than expected with mye-
loablative PBSC transplants from HLA-matched
donors. The 1-year NRM and OS 10% and 69%, re-
spectively, for all patients, and 0% and 88%, respec-
tively, for standard-risk patients. Remarkably, for
a study of myeloablative transplantation from haploi-
dentical donors, mortality from infection was low.
Notably, serious CMV and invasive mold infections,
which are principal causes of infectious death after
allogeneic HSCT, accounted for no deaths in this
study. BK virus–associated cystitis was a major cau-
se of morbidity in these patients, but was nonfatal
and resolved in all patients. The results of our study
demonstrate that myeloablative T cell replete haploi-
dentical HSCT is associated with promising rates of
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option in patients with high-risk malignancies who
do not have HLA-matched donors.
In the past decade, there has been a growing inter-
est in the use of haploidentical HSCT due to the rapid
and nearly universal availability of donors, which is
a critical issue in patients with advanced hematologic
malignancies. Enthusiasm for this approach has been
furthered by significant advances in the field and im-
provements in supportive care, which have allowed
us to more safely provide transplantations for patients
across HLA barriers while mitigating the historic
issues of graft failure and GVHD. This study adds to
a growing body of literature supporting haploidentical
HSCT as a viable alternative for patients without
rapidly available HLA-matched donors.
The optimal approach to performing haploidenti-
cal HSCT remains a matter of study. Aversa et al. [4]
from Perugia have made major contributions to the
field, showing that graft failure and GVHD can be re-
liably controlled using extensive ex vivo T cell deple-
tion, an ATG-containing intensive conditioning
regimen, and highCD341 cell dose in the allograft, re-
sulting in promising outcomes in patients with acute
leukemia. Poor posttransplantation immunity and in-
fectious mortality remain important barriers to the
long-term success of this approach, and recent investi-
gations have focused on improving immune reconstitu-
tion [12,13]. Furthermore, this approach requires
complex and expensive cell selection techniques,
which may not be universally available at all treating
centers.
Huang et al. [14] at Peking University have
avoided the requirement for ex vivo T cell depletion
through the use of an ATG-containing intensive con-
ditioning regimen and an augmented immunosuppres-
sion regimen containing cyclosporine, MMF, and
methotrexate. Durable engraftment, low relapse rates
and encouraging leukemia-free survival was noted,
particularly in younger patients (\35 years of age).
The incidence of grade II-IV aGVHD and cGVHD
was much higher using this approach (55% and 74%,
respectively). The high incidence of cGVHD may
have contributed to both the low rates of disease recur-
rence as well as the increased NRM seen in older pa-
tients.
Another recent approach to myeloablative haplo-
identical allogeneic transplantation was recently de-
scribed by Grosso et al. [15]. Donors underwent
a nonmobilized apheresis on days27 and26 with cells
infused into the recipient on day 25 after completion
of total body irradiation (TBI) of 12 Gy. On days 23
and 22, patients received Cy 60 mg/kg/d  2 days.
On day 0, patients received an extensively T cell de-
pleted PBSC allograft, along with posttransplantation
immunosuppression. All but 2 of the 25 patients
achieved durable engraftment. The incidence of gradeII-IV aGVHD and NRM was 59% and 22%, respec-
tively. Leukemia-free survival was encouraging in
a high-risk patient population; however, our protocol
seems to achieve at least similar outcomes without
the need for ex vivo T cell depletion of the graft.
Luznik et al. [16] at JohnsHopkins University have
taken a different approach based on the use of properly
timed posttransplantation Cy to selectively target acti-
vated alloreactive T cells, which have been shown to be
exquisitely sensitive to alkylator-induced cytotoxicity
[17]. Studies in mice have established that posttrans-
plantation Cy can inhibit both graft rejection and
GVHD in mice receiving T cell replete transplants
[16]. After a nonmyeloablative regimen of fludarabine,
cyclophosphamide, and low-dose TBI of 200 cGy, pa-
tients receive an unmanipulated BM allograft,
posttransplantation Cy, and conventional posttrans-
plantation immunosuppression. Published results
demonstrate low rates of GVHD and NRM, with
promising survival outcomes particularly in patients
with lymphoid malignancies [5]. Similar to other non-
myeloablative approaches, relapse remains the major
source of treatment failure, particularly in patients
with high-risk myeloid malignancies.
The current study tries to build on many of the
successful strategies discussed previously. The use of
posttransplantation Cy seems to provide adequate
control of GVH-directed andHVG-directed alloreac-
tive T cells to achieve reliable donor myeloid and
T cell engraftment. In addition, unlike currently avail-
able ex vivo T cell depletion techniques, posttrans-
plantation Cy seems to more selectively deplete
activated alloreactive T cells, in contrast to resting
T cells, which seems to result in better immune recon-
stitution [18]. Furthermore, there is no requirement
for complex and costly cell section systems. Myeloa-
blative conditioning and the use of PBSC as the cell
source both likely contribute to better disease control
in patients with high-risk hematologic malignancies.
In this study, rates of aGVHD, cGVHD, and NRM
compare favorably to myeloablative matched related
and URD transplantations performed at our institu-
tion. Although overall efficacy is difficult to assess
given the small numbers on the study and the poor dis-
ease risk ofmany patients, survival seems promising for
patients with standard disease risk (majority of patients
with AML who underwent transplantation while in re-
mission), which is certainly comparable to that seen
with HLA-matched donor HSCT.
Noninfectious fevers were experienced by virtually
all patients between day 0 and day 15 after infusion
of haploidentical T cell replete PBSCs. They may be
related to cytokine release from proliferating allo-
reactive cells and consistent with this hypothesis,
they usually resolve after administration of post-
transplantation Cy. In our experience, these fevers
seem to be both more frequent and more severe
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after nonmyeloablative haploidentical BMT using
posttransplantation Cy. These febrile episodes were
managed with acetaminophen and cooling blankets,
as it is our policy not to administer corticosteroids or
other immunosuppressive agents before completion
of the second dose of posttransplantation Cy. In
murine models, properly timed Cy is based on the bi-
ological kinetics of T cell alloreactivity. Posttransplan-
tation Cy is administered when alloreactive T cells are
most susceptible to cytotoxicity. Corticosteroids, or
any T cell immunosuppressive medication, will affect
the kinetics of T cell activation and theoretically re-
duce the efficacy of posttransplantation Cy. It is possi-
ble that the selective nature of Cy-mediated T cell
cytotoxicity results in improved immune recovery,
compared with ex vivo T cell depletion. Consistent
with this, a low rate of mortality from infections was
seen in this study.
An unexpected finding of this study was the high
incidence of hemorrhagic cystitis (HC). Although
there was no mortality associated with this complica-
tion, it caused significant morbidity in patients (dys-
uria, urinary frequency), and 7 patients (35%)
required hospital admission for bladder irrigation
and/or i.v. analgesics. HC is a recognized complication
of allogeneic transplantation therapy. Late-onset HC,
occurring after engraftment, is due almost exclusively
to reactivation of the polyoma BK virus. Other impor-
tant risk factors associated with HC include busulfan-
based conditioning, aGVHD, HLA-mismatched
transplantations, and use of BM as the stem cell source
[19-22]. Retrospective studies have shown high-dose
busulfan, when combined with cyclophosphamide, to
be a significant risk factor for the development of
HC [19-22], particularly in the setting of HLA-
mismatched transplantations, in which HC incidence
ranges from 35% to 58% [19,23,24]. TBI, on the
other hand, has been associated with significantly less
risk of HC in both retrospective series (8% versus
32%) [25] and prospective randomized trials (10% ver-
sus 32%) [26]. In light of these findings, we have initi-
ated a clinical trial of TBI-based myeloablative, T cell
replete haploidentical HSCT.
The results of this approach to myeloablative hap-
loidentical HSCT have been encouraging, and major
historical barriers of graft rejection, GVHD, and
NRM have been significantly addressed. Patients
with advanced disease who are in remission at the
time of transplantation seem to have excellent out-
comes. However, results in patients who undergo
transplantation with chemoresistant disease remain
disappointing. The low rates of infectious complica-
tions and NRM suggest that this approach should be
made available to better-risk patients earlier in the
course of their disease.ACKNOWLEDGMENTS
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